People · Operator

Mark Wiggins

Named in public records as an officer, director or promoter · active 2011–2025 · Biotechnology, Other Technology

2
Companies
7
Filings
$26.3M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
selectIon, Inc.BiotechnologySeries A$19.6M$16.1M2019
OCP Collective Corp.Other TechnologySeries A$6.7M$138.7M2011
Operator network

Mark Wiggins at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Michael Foster · 8 companies · 1 sharedMichael FosterCam Gallagher · 7 companies · 1 sharedCam GallagherAntonius Schuh · 5 companies · 1 sharedAntonius SchuhSteve Zaniboni · 3 companies · 1 sharedSteve ZaniboniDon Scifres · 2 companies · 1 sharedDon ScifresStephen Zaniboni · 2 companies · 1 sharedStephen ZaniboniAndreas Klostermann · 1 companies · 1 sharedAndreas Klosterma…Don Scrifes · 1 companies · 1 sharedDon ScrifesJohn Frankel · 30 companies · 1 sharedJohn FrankelPeter Flint · 14 companies · 1 sharedPeter FlintJohn F. Frankel · 9 companies · 1 sharedJohn F. FrankelRobert Cromer · 1 companies · 1 sharedRobert CromerRobert Prentice · 1 companies · 1 sharedRobert PrenticeselectIon, Inc. · $19.6M raisedselectIon, Inc.OCP Collective Corp. · $6.7M raisedOCP Collective Corp.Mark WigginsMW
Mark Wiggins Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Mark Wiggins on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
John Frankel130
Peter Flint114
John F. Frankel19
Michael Foster18
Cam Gallagher17
Antonius Schuh15
Steve Zaniboni13
Don Scifres12
Stephen Zaniboni12
Andreas Klostermann11
Don Scrifes11
Robert Cromer11
Robert Prentice11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.